Literature DB >> 12543557

Heparin antiproliferative activity on bovine pulmonary artery smooth muscle cells requires both N-acetylation and N-sulfonation.

María O Longas1, Hari G Garg, Jennifer M Trinkle-Pereira, Charles A Hales.   

Abstract

The antiproliferative activity of Heparin (HP) on bovine pulmonary artery smooth muscle cells (BPASMC) in vitro requires both N-acetylation and N-sulfonation. This was demonstrated by quantifying the relative N-acetylation of three commercial heparins of known antiproliferative activities, using their Fourier-transform infrared (FTIR) band areas at 1381-1378 and 1320-1317 cm(-1), which combined resulted in 1.0, 1.0 and 1.3 cm2 for Choay, Elkins-Sinn and Upjohn HP, respectively. These results show that Upjohn HP, which is at least 44% more antiproliferative than the other two, is 30% more N-acetylated. Upjohn HP was also N-desulfonated chemically, and its antiproliferative activity was determined. Its total sulfonate (--SO 3 -) content (O- and N-sulfonate) was quantified using the FTIR band area at 1260-1200 cm(-1) for the S=O stretching; a drop in sulfonate content from 21.87% (w/w) before N-desulfonation to 16.51% (w/w) after N-desulfonation, resulted in a 67% decrease in its inhibitory potency. In addition to the requirement that approximately 24% of the sulfonate content be bonded to N, the data show a direct correlation between the extent of Upjohn HP N-acetylation and its antiproliferative activity on BPASMC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543557     DOI: 10.1016/s0008-6215(02)00441-x

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  8 in total

1.  Effect of heparin oligomer chain length on the activation of valvular interstitial cells.

Authors:  Sara Pedron; Andrea M Kasko; Carmen Peinado; Kristi S Anseth
Journal:  Biomacromolecules       Date:  2010-06-14       Impact factor: 6.988

2.  Effect of carboxyl-reduced heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Craig Freeman; Boyangzi Li; Fuming Zhang; Robert J Linhardt; Charles A Hales
Journal:  Carbohydr Res       Date:  2010-03-21       Impact factor: 2.104

3.  Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle.

Authors:  Varsha Kanabar; Stuart J Hirst; Brian J O'Connor; Clive P Page
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

4.  Anti-proliferative effects of O-acyl-low-molecular-weight heparin derivatives on bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Charles A Hales; Boyangzi Li; Casey N Moore; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2011-07-20       Impact factor: 2.916

5.  Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle.

Authors:  V Kanabar; C P Page; D E Simcock; C Karner; K Mahn; B J O'Connor; S J Hirst
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Significance of the 2-O-sulfo group of L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells.

Authors:  Hari G Garg; Hicham Mrabat; Lunyin Yu; Craig Freeman; Boyangzi Li; Fuming Zhang; Robert J Linhardt; Charles A Hales
Journal:  Carbohydr Res       Date:  2008-07-04       Impact factor: 2.104

Review 7.  Exopolysaccharides produced by marine bacteria and their applications as glycosaminoglycan-like molecules.

Authors:  Christine Delbarre-Ladrat; Corinne Sinquin; Lou Lebellenger; Agata Zykwinska; Sylvia Colliec-Jouault
Journal:  Front Chem       Date:  2014-10-08       Impact factor: 5.221

8.  Acetylation may strengthen the antitumor activity of low molecular heparin.

Authors:  Ying Liang; Guixin Duan; Yuanyuan Wang; Guowen Wang; Ansheng Wang; Kangwu Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.